Hemorheological properties in patients with type-1 and type-2 diabetes mellitus
Paper #3219 received 16 Jan 2017; revised manuscript received 15 Feb 2017; accepted for publication 15 Jun 2017; published online 13 Jul 2017.
The hemorheologic disorders, which are potentially deleterious in a wide range of pathologies, were studied in patients with type-1 and type-2 diabetes mellitus. The significant determinants of blood viscosity, red blood cells (RBC) deformability and RBC reversible aggregation were assessed by ektacytometry and by laser backscattering technique, respectively. For both types of the disease, we observed acceleration of the first phase of RBC aggregation that contrasted with its deceleration at the second phase. The hydrodynamic stability of the aggregates, especially the smallest ones, exceeded the normal values in both cases. The influence of GP IIb/IIIa receptor inhibitor, monafram on RBC aggregation and disaggregation was the same in the cases of patients and normal subjects. The maximal shear induced RBC stretching exceeded the normal one in patients of both groups. The data reveal not only pathological but also compensatory character of hemorheological alterations in patients with type-1 and type-2 diabetes mellitus.
1. H. J. Meiselman, “Red blood cell aggregation: 45 years being curious,” Biorheology 46(1), 1–19 (2009).
2. J. Radosinska, and N. Vrbjar, “The role of red blood cell deformability and Na,K-ATPase function in selected risk factors of cardiovascular diseases in humans: focus on hypertension, diabetes mellitus and hypercholesterolemia,” Physiol. Res. 65(Suppl. 1), S43-S54 (2016).
3. S. Mendis, S. Davis, and B. Norrving, “Organizational Update: The World Health Organization Global Status Report on Noncommunicable Diseases 2014; One More Landmark Step in the Combat Against Stroke and Vascular Disease,” Stroke 46, e121-e122 (2015).
4. P. Vague, and I. Juhan, “Red cell deformability, platelet aggregation, and insulin action,” Diabetes 32(Suppl. 2), 88-91 (1983).
5. C. Lacombe, C. Bucherer, and J. C. Lelievre, “Hemorheological improvement after Daflon 500 mg treatment in diabetes,” Int. Angiol. 7(Suppl. 2), 21-24 (1988).
6. M. Cho, S. Shin, H. M. Kwon, H. Chung, and B. K. Lee, “Effect of clinical and RBC hemorheological parameters on myocardial perfusion in patients with type 2 diabetes mellitus,” Biorheology 51(2-3), 215-226 (2014).
7. N. Pargalava, M. Mantskava, and G. Mchedlishvili, “Regional and systemic hemorheological disorders during feet diabetic gangrene,” Clin. Hemorheol. Microcirc. 30(3-4), 457-459 (2004).
8. G. Cicco, and S. Cicco, “Hemorheology and microcirculation in some pathologies of internal medicine,” Minerva Med. 98(6), 625-631 (2007) [in Italian].
9. S. Chien, and K.-M. Jan, “Ultrastructure basis of the mechanism of rouleaux formation,” Microvascular Research 5, 155-166 (1973). Crossref
10. D. Lominadze, and W. Dean, “Involvement of fibrinogen specific binding in erythrocyte aggregation,” FEBS Lett. 513(1-3), 41–44 (2002). Crossref
11. I. A. Sokolova, A. V. Muravyov, M. D. Khokhlova, S. Y. Rikova, E. V. Lyubin, M. A. Gafarova, M. N. Skryabina, A. A. Fedyanin, D. V. Kryukova, and A. A. Shahnazarov, “An effect of glycoprotein IIb/IIIa inhibitors on the kinetics of red blood cells aggregation,” Clin. Hemorheol. Microcirc. 57(3), 291-302 (2014).
12. E. Straface, R. Rivabene, R. Masella, M. Santulli, R. Paganelli, and W. Malorni, “Structural changes of the erythrocyte as a marker of non-insulin-dependent diabetes: protective effects of N-acetylcysteine,” Biochem. Biophys. Res. Commun 290(5), 1393-1398 (2002). Crossref
13. M. Donner, M. Siadat, and J. F. Stoltz, “Erythrocyte aggregation: approach by light scattering determination,” Biorheology 25(1-2), 367-375 (1988).
14. M. Bessis, and N. Mohandas, “A diffractometric method for the measurement of cellular deformability,” Blood Cells 8(3), 307-313 (1975).
15. T. V. Korotaeva, N. N. Firsov, A. Bjelle, and M. A. Vishlova, “Erythrocytes aggregation in healthy donors at native and standard hematocrit: the influence of sex, age, immunoglobulins and fibrinogen concentrations. Standardization of parameters,” Clin. Hemorheol. Microcirc. 36(4), 335-343 (2007).
16. N. N. Firsov, N. V. Klimova, A. V. Priezzhev, and A. Yu. Tyurina, “Fundamental laws of the deformational behaviour of erythrocytes in shear flow,” Journal of Engineering Physics and Thermophysics 79(1), 118-124 (2006) [in Russian]. Crossref
17. O. V. Filatova, A. A. Sidorenko, and S. A. Agarkova, “Effects of age and sex on rheological properties of blood,” Human Physiology 41(4), 437-443 (2015) [in Russian]. Crossref
18. M. Mantskava, N. Momtselidze, N. Pargalava, and G. Mchedlishvili, “Hemorheological disorders in patients with type 1 or 2 diabetes mellitus and foot gangrene,” Clin. Hemorheol. Microcirc. 35(1-2), 307-310 (2006).
19. I. Sokolova, M. Gafarova, M. Khokhlova, A. Muravyev, E. Lyubin, M. Skryabina, A. Fedyanin, T. Krasnova, and A. Shahnazarov, “Glycoprotein IIB-IIIA inhibitor, monafram decelerate the early phase of red blood cells aggregation,” Journal of Cellular Biotechnology 2(1), 15-22 (2016). Crossref
20. W. Subasinghe, and D. M. Spence, “Simultaneous determination of cell aging and ATP release from erythrocytes and its implications in type 2 diabetes,” Anal. Chim. Acta. 618(2), 227-233 (2008).
© 2014-2020 Samara National Research University. All Rights Reserved.
Public Media Certificate (RUS). 12+